首页> 美国卫生研究院文献>Clinical and Developmental Immunology >Association between B Cell Growth Factors and Primary Sjögrens Syndrome-Related Autoantibodies in Patients with Non-Hodgkins Lymphoma
【2h】

Association between B Cell Growth Factors and Primary Sjögrens Syndrome-Related Autoantibodies in Patients with Non-Hodgkins Lymphoma

机译:非霍奇金淋巴瘤患者中B细胞生长因子与原发性Sjögren综合征相关自身抗体之间的关联

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the overall success of using R-CHOP for the care for non-Hodgkin's lymphoma patients, it is clear that the disease is quite complex and new insight is needed to further stratify the patient for a better personized treatment. In current study, based on previous studies from animal model, new panels combining well-established cytokine (BAFF) and autoantibodies (anti-SSA/Ro) with newly identified cytokine (IL14) and autoantibodies (TSA) were used to evaluate the association between B cell growth factor and Sjögren's related autoantibodies in NHL patients. The result clearly indicates that there was a unique difference between BAFF and IL14 in association with autoantibodies. While serum BAFF was negatively associated with the presence of both traditional anti-SSA/Ro and novel TSA antibodies in GI lymphoma patient, IL14 was positively associated with the presence of both traditional anti-SSA/Ro and novel TSA antibodies in non-GI lymphoma patient. Long-term follow-ups on these patients and evaluation of their response to the R-CHOP treatment and recurrence rate will be very interesting. Our result provides a solid evidence to support using novel diagnostic panel to better stratify the NHL patients.
机译:尽管使用R-CHOP治疗非霍奇金淋巴瘤患者取得了总体成功,但很明显,该疾病非常复杂,需要新的见识以进一步对患者进行分层以进行更好的个性化治疗。在当前的研究中,基于对动物模型的先前研究,使用新建立的结合成熟细胞因子(BAFF)和自身抗体(anti-SSA / Ro)与新近鉴定的细胞因子(IL14)和自身抗体(TSA)的组合来评估NHL患者的B细胞生长因子和Sjögren相关的自身抗体。结果清楚地表明,BAFF和IL14与自身抗体之间存在独特的区别。虽然GI淋巴瘤患者血清BAFF与传统抗SSA / Ro和新型TSA抗体均呈负相关,但IL14与非GI淋巴瘤与传统抗SSA / Ro和新型TSA抗体均呈正相关患者。对这些患者进行长期随访并评估他们对R-CHOP治疗的反应和复发率将非常有趣。我们的结果提供了坚实的证据来支持使用新型诊断专家组更好地对NHL患者进行分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号